BIAYA PENGOBATAN PASIEN KANKER PAYUDARA STADIUM AWAL YANG MENDAPATKAN KEMOTERAPI KOMBINASI 5- FLUOROURASIL, DOKSORUBISIN, SIKLOFOSFAMID (FAC) DENGAN KEMOTERAPI KOMBINASI BERBASIS TAXAN

Main Authors: , Didik Setiawan S. Farm, , Prof. dr. Iwan Dwiprahasto, M.Med.Sc., Ph.D.
Format: Thesis NonPeerReviewed
Terbitan: [Yogyakarta] : Universitas Gadjah Mada , 2011
Subjects:
ETD
Online Access: https://repository.ugm.ac.id/90026/
http://etd.ugm.ac.id/index.php?mod=penelitian_detail&sub=PenelitianDetail&act=view&typ=html&buku_id=52348
Daftar Isi:
  • Background: Cancer is an important problem in health and economics. It caused by high morbidity and mortality rate, bad prognosys and chemotherapy resistance which cause the number of cancer patient increase annually. Appropriate selection of combination chemotherapy has an important role to outcome therapy in breast cancer patient. One of the recommended combination chemotherapy for early stage breast cancer are antracyclin and taxan based. Objective: the research puspose is to find out the cost of treatment differences in early stage breast cancer whose get combination chemotherapy FAC and taxan based. Methods: the method of this research is observational analytic study with cross sectional design and the data collection method is retrospective to medical records and hospital information systems. Results: From 110 patients who is included in research population, 61 (54.45%) patient get FAC combination and 49 (44.55%) patient get taxan based combination. Mean of patient age is 47,76 years old. Cost of treatment of patient with FAC combination is paid by insurance (50,8) but patient with taxan based chemotherapy is paid by non-insurance (38,8). Most patient with taxan based combination is on stage IIB (53,1%) at the first diagnosed, but most of patient with FAC combination is on stage IIA and IIB (32.8%). The results of immunohistichemical examination is said that most of patient has negative estrogen receptor, progesterone receptor and p53 protein. Patient with taxan based combination chemotherapy has worse intermediate outcome than FAC combination. It seen at longer length of stay, lower in completed chemotherapy cycle and worse survival profile for each breast cancer stage and age. Patient with taxan combination has a higher compliance in chemotherapy schedule. Conclusion: Cost of treatment in breast cancer patient with taxan based chemotherapy combination is almost three times higher than patient with FAC combination buat patient with taxan combination has a worse intermediate outcome than patient with FAC combination.